May 31, 2023
by Bohdana Sokolova
Biopharma insight
XtalPi Inc., a company that uses artificial intelligence (AI) and automation in pharmaceutical technology, is set to collaborate with Eli …
May 15, 2023
by Natalia Honchar
Biopharma insight
When we hear “AI in drug discovery”, there is a high chance our imagination would draw a small molecule discovery …
May 10, 2023
by Andrii Buvailo
Biopharma insight
In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire …
April 1, 2023
by Andrii Buvailo
Biopharma insight
The monoclonal antibodies (mAbs) market has seen impressive growth in recent years, with the top-selling drugs increasingly being mAbs. The …
Feb. 4, 2023
by Andrii Buvailo
Biopharma insight
Since a revolutionary discovery of penicillin in 1928 by Scottish bacteriologist and Nobel laureate Alexander Fleming, numerous inventions of new …
Jan. 26, 2023
by Andrii Buvailo
News
British Patient Capital, a subsidiary of the British Business Bank, invested $7 million in Grey Wolf Therapeutics, an Oxford-based biotech …
Nov. 29, 2022
by Andrii Buvailo
Biopharma insight
Molecular mechanics (MM) is a traditional computational approach when it comes to modeling in synthetic organic chemistry, medicinal chemistry, and …
Nov. 20, 2022
by Bohdana Sokolova
Biopharma insight
Despite the economic situation and political climate in 2022, such fields as drug discovery and biotech keep evolving and bringing …
Nov. 14, 2022
by BiopharmaTrend
Biopharma insight
The community of AI-driven biotech companies is continuously expanding, adding new players to the drug discovery race. In 2021 several …
Nov. 3, 2022
by Bohdana Sokolova
Biopharma insight
While Spain's biotechnology research centers, including the University of Barcelona and Pompeu Fabra University, retain their positions in world rankings, …
Aug. 18, 2022
by Bohdana Sokolova
Biopharma insight
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, …
Aug. 15, 2022
by Andrii Buvailo
Interview
Luciano Santollani is currently working towards his PhD at MIT developing novel cancer therapeutics, and is also working as a …